Solvay's Creon gets FDA "approvable" letter

2 September 2007

Solvay Pharmaceuticals, the US subsidiary of Belgian drug and chemicals firm Solvay, says it has received an "approvable" letter from the Food and Drug Administration for its drug Creon (pancrelipase delayed-release capsules). The firm needs to provide additional clinical data, and Chemistry, Manufacturing and Controls information to the federal agency prior to approval

Creon, which is a treatment for the pancreatic exocrine insufficiency associated with cystic fibrosis, has been marketed in the USA for 20 years. Solvay explained that it submitted the drug to the FDA in an effort to comply with the agency's 2004 publication of a Federal Register Notice requesting that all manufacturers of pancreatic enzyme products obtain New Drug Application approval.

Laurence Downey, president and chief executive of Solvay Pharmaceuticals, said: "we are confident that our ongoing clinical work that was initiated prior to receiving this letter will satisfy the FDA's request."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight